CytomX Therapeutics, Inc. (CTMX)

1.6180 -0.0120 (-0.74%) As of 10:05AM EDT. Market open.

CytomX Therapeutics, Inc.

151 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650 515 3185
https://www.cytomx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 120

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sean A. McCarthy DPHIL	Chairman & CEO	1.03M	N/A	1967
Dr. Marcia P. Belvin Ph.D.	Senior VP & Chief Scientific Officer	634.83k	N/A	N/A
Mr. Jeffrey Landau B.S., M.B.A.	Senior VP, Head of Strategy & Chief Business Officer	580.69k	N/A	1979
Mr. Christopher W. Ogden	Senior VP of Finance & Accounting	N/A	N/A	1984
Mr. Lloyd A. Rowland Jr., J.D.	Senior VP, General Counsel, Chief Compliance Officer & Secretary	608.72k	N/A	1957
Ms. Danielle Olander-Moghadassian	Senior VP & Chief Human Resources Officer	N/A	N/A	N/A
Ms. Leslie Robbins	Senior Vice President of Intellectual Property	N/A	N/A	N/A
Dr. Yu-Waye Chu M.D.	Senior VP & Chief Medical Officer	N/A	N/A	1969
Ms. Dawn Benson	Senior Vice President of Quality & Product Manufacturing	N/A	N/A	N/A
Dr. Hoyoung Huh M.D., Ph.D.	Special Advisor to Chief Executive Officer	72.5k	N/A	1969

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Corporate governance

CytomX Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.